HRMY — Harmony Biosciences Holdings, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1802665 ·
Last close
$39.60
Market Cap
$2.31B
52W High
$43.49
52W Low
$25.52
ADV30
991,714
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 261,280,000 | 198,082,000 | 89,316,000 | 75,431,000 | 1,373,084,000 | 549,769,000 | 373,841,000 |
| Mar 2026 | 215,387,000 | 170,875,000 | 37,291,000 | 32,488,000 | 1,271,824,000 | 589,398,000 | 361,475,000 |
| Dec 2025 | 243,776,000 | 175,231,000 | 38,557,000 | 22,486,000 | 1,271,631,000 | 752,502,000 | 401,413,000 |
| Sep 2025 | 239,455,000 | 179,805,000 | 65,487,000 | 50,865,000 | 1,208,218,000 | 646,999,000 | 373,095,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$355,077,000
Investing CF
$-337,571,000
Financing CF
$-13,787,000
CapEx
$-310,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$3.08
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$268,822,000
Inventory
$6,360,000
Receivables
$110,995,000
ST Investments
$118,022,000
EBIT TTM
$254,673,000
Pretax Income TTM
$241,202,000
Interest Exp TTM
$13,471,000
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$959,897,984
EBITDA
$255,987,008
Free Cash Flow
$182,835,504
Enterprise Value
$1,910,375,040
Total Cash
$667,790,976
Total Debt
$160,191,008
Shares Out
58,236,393
Trailing EPS
$3.09
Book Value
$17.19
ROE
20.5%
ROA
11.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 868,453,000 | 208,469,000 | 158,687,000 | 1,271,631,000 | 401,413,000 | 870,218,000 | 348,199,000 |
| Dec 2024 | 714,734,000 | 190,826,000 | 145,493,000 | 999,200,000 | 340,045,000 | 659,155,000 | 219,821,000 |
| Dec 2023 | 582,022,000 | 192,030,000 | 128,853,000 | 811,448,000 | 344,456,000 | 466,992,000 | 219,387,000 |
| Dec 2022 | 437,855,000 | 120,186,000 | 181,468,000 | 673,870,000 | 271,032,000 | 402,838,000 | 144,466,000 |
TTM Snapshot
Revenues TTM
$899,107,000
NetIncome TTM
$145,615,000
OpCashFlow TTM
—
Assets (Latest)
$1,271,824,000
Forward EPS
$6.69
Max Pain — expiry 2026-12-18
max pain strike: $37.50 · spot: $39.84 · call oi: 2,519 · put oi: 11,176
Expected Move to 2026-12-18:
±$9.90
(24.85%) —
implied range
$29.94 –
$49.74
· ATM straddle on $40.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NRIX | Nurix Therapeutics, Inc. | $2.30B | $22.21 | — |
| IRON | Disc Medicine, Inc. | $2.33B | $60.77 | — |
| SLS | SELLAS Life Sciences Group, Inc. | $2.27B | $11.26 | — |
| PBH | Prestige Consumer Healthcare Inc. | $2.27B | $47.87 | — |
| BHC | Bausch Health Companies Inc. | $2.26B | $6.04 | — |
News headlines (Yahoo Finance, 1h cache)
Harmony Biosciences (HRMY) Heads To European Narcolepsy Days With New Phase 3 Data
2026-10-08 20:10 · Yahoo
Harmony Biosciences (HRMY) Stock Looks Below Fair Value As Shares Rose 48%
2026-10-08 18:16 · Yahoo
Harmony BioSciences' Wakix Franchise, Pipeline Offer Multiple Value Drivers, Oppenheimer Says
2026-10-08 15:45 · Yahoo
HRMY vs. CSLLY: Which Stock Is the Better Value Option?
2026-10-06 14:40 · Yahoo
Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?
2026-10-06 12:40 · Yahoo
Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report?
2026-09-03 15:30 · Yahoo
Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress
2026-09-03 12:05 · Yahoo
Harmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy Pipeline
2026-08-14 14:04 · Yahoo
Harmony Biosciences (HRMY) Q2 2026 Earnings Call Transcript
2026-08-11 17:29 · Yahoo
Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days
2026-10-01 12:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.